Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Gritstone bio (GRTS) Stock Forecast & Price Target

Gritstone bio logo
Get the Latest News and Ratings for GRTS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Gritstone bio and its competitors.

Sign Up

GRTS Analyst Ratings Over Time

TypeCurrent Forecast
11/26/23 to 11/25/24
1 Month Ago
10/27/23 to 10/26/24
3 Months Ago
8/28/23 to 8/27/24
1 Year Ago
11/26/22 to 11/26/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$2.17$2.17$4.75$7.33
Forecasted UpsideN/A6,628.78% Upside875.36% Upside435.28% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Buy
Buy

GRTS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

GRTS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Gritstone bio Stock vs. The Competition

TypeGritstone bioMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted UpsideN/A26,841.36% Upside6.58% Upside
News Sentiment Rating
Neutral News

See Recent GRTS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/2/2024B. Riley
4 of 5 stars
 Reiterated RatingBuy ➝ Neutral$3.00 ➝ $1.00+354.74%
10/1/2024Evercore ISI
2 of 5 stars
J. Miller
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/1/2024HC Wainwright
2 of 5 stars
S. Lee
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$4.00 ➝ $0.50+98.49%
10/1/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Buchanan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
9/28/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$6.00 ➝ $7.00+488.23%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:21 PM ET.


GRTS Forecast - Frequently Asked Questions

According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Gritstone bio is $2.17, with a high forecast of $5.00 and a low forecast of $0.50.

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone bio in the last twelve months. There are currently 3 hold ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GRTS shares.

According to analysts, Gritstone bio's stock has a predicted upside of ∞ based on their 12-month stock forecasts.

Over the previous 90 days, Gritstone bio's stock had 2 downgrades and 1 upgrade by analysts.

Gritstone bio has been rated by research analysts at B. Riley, Evercore ISI, HC Wainwright, and JMP Securities in the past 90 days.

Analysts like Gritstone bio less than other "medical" companies. The consensus rating score for Gritstone bio is 2.50 while the average consensus rating score for "medical" companies is 2.80. Learn more on how GRTS compares to other companies.


This page (NASDAQ:GRTS) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners